JW Holdings Corporation operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares JW Holdings with three other
companies in this sector in South Korea:
sales of 177.77 billion Korean Won [US$157.33 million]
of which 91%
(144.44 billion Korean Won [US$127.83 million]
Kyongbo Pharmaceutical Co Ltd
(191.66 billion Korean Won [US$169.62 million]
of which 100%
was Drugs & Pharmaceutical Raw Materials).
JW Holdings reported sales of 683.72 billion Korean Won (US$605.09 million)
December of 2017.
a very small
increase of 0.5%
versus 2016, when the company's sales were 680.48 billion Korean Won.
Sales at JW Holdings have increased during each of the previous five years
(and since 2012, sales have increased a total of 34%).
Sales of Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
22.9% in 2017, from
610.89 billion Korean Won to 750.70 billion Korean Won.
JW Holdings also saw significant increases in sales in
Other Segment (up 5.5% to 29.18 billion Korean Won)
Control Business (up 11.1% to 27.25 billion Korean Won)
Not all segments of JW Holdings experienced an increase in sales in 2017:
sales of Medical Equipment fell 17.6% to 86.34 billion Korean Won.